Compare ALC & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALC | NTRA |
|---|---|---|
| Founded | 1945 | 2003 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0B | 32.9B |
| IPO Year | N/A | 2015 |
| Metric | ALC | NTRA |
|---|---|---|
| Price | $78.52 | $208.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $88.29 | ★ $253.79 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 02-24-2026 | 02-27-2026 |
| Dividend Yield | ★ 0.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $10,185,000,000.00 | $2,116,676,000.00 |
| Revenue This Year | $5.76 | $33.95 |
| Revenue Next Year | $7.24 | $16.72 |
| P/E Ratio | $36.56 | ★ N/A |
| Revenue Growth | 4.34 | ★ 38.17 |
| 52 Week Low | $71.55 | $125.38 |
| 52 Week High | $99.20 | $256.36 |
| Indicator | ALC | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 36.52 |
| Support Level | $77.95 | $203.86 |
| Resistance Level | $81.05 | $214.36 |
| Average True Range (ATR) | 1.37 | 8.80 |
| MACD | -0.14 | -2.38 |
| Stochastic Oscillator | 29.92 | 25.14 |
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.